Stock 600211 TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.
Add to a list
To use this feature you must be a member
Log inSign up

Tibet Rhodiola Pharmaceutical Holding Co. Stock

Equities

600211

CNE000000ZW7

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
36.7 CNY +0.27% Intraday chart for Tibet Rhodiola Pharmaceutical Holding Co. +1.38% -2.23%
Apr. 26 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 26 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 3.44B 475M Sales 2025 * 4.07B 562M Capitalization 11.83B 1.63B
Net income 2024 * 1.02B 142M Net income 2025 * 1.23B 169M EV / Sales 2024 * 3.44 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.91 x
P/E ratio 2024 *
11.6 x
P/E ratio 2025 *
9.64 x
Employees 601
Yield 2024 *
-
Yield 2025 *
-
Free-Float 37.89%
More Fundamentals * Assessed data

Chart Tibet Rhodiola Pharmaceutical Holding Co.

Dynamic Chart

Latest news about Tibet Rhodiola Pharmaceutical Holding Co.

Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chengdu Nuo´en Genomics Co., Ltd. announced that it has received funding from Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), Tibet Rhodiola Pharmaceutical Holding Co. CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tibet Rhodiola Pharma Unit Becomes Authorized Marketer of Heart Drug MT
Tibet Rhodiola Pharma Sees 81% Jump in 2022 Profit MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tibet Rhodiola Pharma Wins License to Produce Chest Pain Tablets MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) added to Shanghai Stock Exchange A Share Index CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) dropped from Shanghai Stock Exchange A Share Index CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news

Quotes and Performance

1 day+0.27%
1 week+1.38%
1 month+5.34%
3 months+25.78%
6 months-3.69%
Current year-2.23%
More quotes

Highs and lows

1 week
35.08
Extreme 35.0769
37.37
1 month
33.52
Extreme 33.5154
37.37
Current year
26.95
Extreme 26.9538
38.16
1 year
26.95
Extreme 26.9538
49.59
3 years
22.73
Extreme 22.7308
56.15
5 years
15.47
Extreme 15.4669
140.05
10 years
10.98
Extreme 10.9834
140.05
More quotes

Managers and Directors - Tibet Rhodiola Pharmaceutical Holding Co.

Managers TitleAgeSince
Yuan Dong Guo CEO
 Chief Executive Officer 54 -
Jun Chen DFI
 Director of Finance/CFO 46 11-12-31
Yu Cheng Zhou BRD
 Director/Board Member 42 -
Members of the board TitleAgeSince
Da Bin Chen CHM
 Chairman 68 -
Yu Cheng Zhou BRD
 Director/Board Member 42 -
San Yan Wu BRD
 Director/Board Member 43 -
More insiders

ETFs positioned on Tibet Rhodiola Pharmaceutical Holding Co.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.62% -
More ETFs positioned on Tibet Rhodiola Pharmaceutical Holding Co.

Quotes

Date Price Change Volume
24-04-30 36.7 +0.27% 6,108,548
24-04-29 36.6 +0.49% 7,624,806
24-04-26 36.42 +0.62% 4,573,311
24-04-25 36.2 -0.88% 3,126,889
24-04-24 36.52 -0.57% 4,404,515

End-of-day quote Shanghai S.E., April 29, 2024

More quotes

Company Profile

TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The Company conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-14 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Tibet Rhodiola Pharmaceutical Holding Co.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
36.7
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. Stock Tibet Rhodiola Pharmaceutical Holding Co.
-2.23% 1.63B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.15% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.18% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.37% 325B
ABBVIE INC. Stock AbbVie Inc.
+4.93% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-4.17% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600211 Stock